-

FogPharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--FogPharma®, a clinical-stage precision medicine biopharmaceutical company committed to transforming the lives of patients facing devastating diseases through the discovery of life changing and lifesaving therapeutics using its Helicon™ peptide platform, today announced that Mathai Mammen, M.D., Ph.D., chairman, president and chief executive officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 3:30 p.m. Pacific Time. In addition, Dr. Mammen will participate in the opening keynote panel “State of Innovation 2024” at the WuXi Global Forum 2024 on the same day at 1:30 p.m. Pacific Time.

Additional information about FogPharma can be found on the company’s website at www.fogpharma.com.

About FogPharma®

FogPharma is a clinical-stage biopharmaceutical company that seamlessly integrates breakthroughs in bench science and data science to create transformative precision therapeutics for patients suffering from devastating and often fatal diseases such as cancer. FogPharma’s discovery engine creates Helicon™ therapeutics, which are a new generation of ultra-diverse, highly tunable peptide drugs capable of modulating virtually any protein implicated in disease. Our robust and wholly owned pipeline of programs is currently focused on cancer targets that are intractable to small molecules and biotherapeutics. The company’s lead program, FOG-001, is a long sought-after blocker of β-catenin:TCF interactions that is currently being evaluated in a Phase 1/2 clinical trial in patients with Wnt/β-catenin signaling pathway-activated solid tumors, including colorectal cancer. FogPharma has raised more than $350 million to date from top investors and is led by an experienced team of industry experts. FogPharma is headquartered in Cambridge, MA. For more information, please visit www.fogpharma.com.

©2024 Fog Pharmaceutical, Inc. FOGPHARMA is a registered trademark of Fog Pharmaceuticals, Inc.

Contacts

1AB
Dan Budwick
dan@1abmedia.com

Industry:

FogPharma

Release Versions
English

Contacts

1AB
Dan Budwick
dan@1abmedia.com

More News From FogPharma

FogPharma Announces First Patient Dosed in Phase 1/2 Clinical Trial of First-in-class TCF-blocking β-catenin Inhibitor, FOG-001, in Advanced Solid Tumors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--FogPharma®, a biopharmaceutical company committed to transforming the lives of patients through a new precision medicine approach widely applicable to important and challenging intracellular targets, today announced the first patient has been dosed in a first-in-human Phase 1/2 clinical trial of, FOG-001, the company’s first-in-class TCF-blocking β-catenin inhibitor. FOG-001 represents the first development candidate arising from FogPharma’s pioneering Helicon...

Mathai Mammen, M.D., Ph.D., to Join FogPharma as Chairman, President and Chief Executive Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--FogPharma®, a biopharmaceutical company committed to transforming the lives of patients through a new precision medicine approach widely applicable to important and challenging intracellular targets, today announced that Mathai Mammen, M.D., Ph.D., will join the company as chairman, president and chief executive officer. Dr. Mammen brings significant global R&D and corporate leadership experience to FogPharma, having most recently served as executive vice...

FogPharma Announces $178 Million Series D Financing to Advance Pipeline of First-in-Class Helicon Polypeptide Therapeutics Targeting Major Cancer Drivers

CAMBRIDGE, Mass.--(BUSINESS WIRE)--FogPharma®, a biopharmaceutical company pioneering a new class of precision medicines that could ultimately prove applicable to the vast majority of therapeutic targets, including those previously considered “undruggable,” today announced a $178 Million Series D financing. The financing round includes new investors ARCH Venture Partners, Milky Way Investments and Fidelity Management & Research Company and existing investors VenBio Partners, Deerfield Manag...
Back to Newsroom